di-Ellipticine-RIBOTAC TFA
di-Ellipticine-RIBOTAC TFA is a RNase recruiting chimera (RIBOTAC) degrader, capable of specifically binding and degrading expanded G4C2 RNA repeat (r(G4C2)exp). di-Ellipticine-RIBOTAC TFA selectively binds the three-dimensional (3D) structure formed by r(G4C2)exp and that recruits an endogenous ribonuclease (RNase) to cleave r(G4C2)exp. di-Ellipticine-RIBOTAC TFA selectively degrades the mutant chromosome 9 open reading frame 72 (C9orf72) allele and reduces quantities of toxic dipeptide repeat proteins (DPRs) translated from r(G4C2)exp. di-Ellipticine-RIBOTAC TFA significantly improves the pathological phenotype of amyotrophic lateral sclerosis/ frontotemporal dementia (c9ALS/FTD) in cells and mouse models. di-Ellipticine-RIBOTAC TFA can be used for the study of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD).
For research use only. We do not sell to patients.
- CAS No.: 2767983-77-5
- Formula: C80H88F3N7O18S
- Molecular Weight:1524.65
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
All DNA/RNA Synthesis Isoforms
More
Biological Activity
di-Ellipticine-RIBOTAC (compound 7) (5-500 nM) TFA inhibits RAN translation of r(G4C2)66 in HEK293T cells, and reduces quantities of the r(G4C2)exp-containing transcript in a dose-dependent fashion[1].
di-Ellipticine-RIBOTAC (5-500 nM) TFA selectively reduces C9orf72 intron 1 abundance with an IC50 of ~50 nM. di-Ellipticine-RIBOTAC TFA also reduces poly(GP) abundance in c9ALS patient-derived lymphoblastoid cell lines (LCLs) and c9ALS patient-derived induced pluripotent stem cells (iPSCs)[1].
di-Ellipticine-RIBOTAC (50 nM; 2.5 weeks) TFA reduces C9orf72 transcripts containing the r(G4C2)exp repeat in intron 1 in iPSC-derived spinal motor neurons (iPSNs) from c9ALS patients and reversed the loss of Nup98[1].
di-Ellipticine-RIBOTAC TFA cleaves Cy5- and Cy3-labeled r(G4C2)8 RNA in the presence of RNase L[1].
di-Ellipticine-RIBOTAC TFA inhibits hnRNP H1 binding to r(G4C2)8 RNA (IC50 = 2.4 μM)[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:+/+PWR500 (12-25 weeks old) (expressing 500 r(G4C2) repeats)[1]
-
Dosage:33 nmol
-
Administration:i.c.v.; single dose
-
Result:Reduced r(G4C2)exp-containing intron 1 mRNA abundance by 44% compared to vehicle-treated controls, decreased the number of r(G4C2)exp-containing nuclear foci, reduced poly(GP) abundance by 74% in brain tissue, decreased poly(GP) and poly(GA) aggregates, and decreased TDP-43 inclusions.
Chemical Information
-
CAS No. 2767983-77-5
-
Molecular Weight 1524.65
-
Formula C80H88F3N7O18S
-
SMILES
CCOC(C1=C(S/C(C1=O)=C\C2=CC=C(C(O)=C2)OCCOCCOCCOCCNC(CCC(N(CCOCCOCCOC3=CC4=C(NC5=C4C(C)=C6C=NC=CC6=C5C)C=C3)CCOCCOCCOC7=CC=C8NC9=C(C(C)=C%10C=NC=CC%10=C9C)C8=C7)=O)=O)NC%11=CC=CC=C%11)=O.OC(C(F)(F)F)=O
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
di-Ellipticine-RIBOTAC TFA Related Classifications
HY-141878A Related Classifications
Powered by Bioz
- di-Ellipticine-RIBOTAC
- 2767983-77-5
- RIBOTAC
- DNA/RNA Synthesis
- RNase L
- C9orf72
- rodent model
- r(G2C4)exp
- c9ALS/FTD
- FVB/NJ-Tg(C9orf72)500Lpwr/J (PWR500) mice
- HEK293T cells
- dipeptide repeat proteins
- Neurological Disease
- c9ALS patient-derived iPSCs
- c9ALS patient-derived iPSNs
- c9ALS patient-derived spinal neurons
- Nup98
- hnRNP H1
- c9ALS patient-derived LCLs
- Inhibitor
- inhibitor
- inhibit